Ten years have passed since Reig Jofre – a pharmaceutical company with more than 95 years of experience dedicated to researching, developing, manufacturing and marketing health solutions – made its debut on the Spanish stock markets. Since then, the company has strengthened its growth and consolidated its position as a key player in both the national and international pharmaceutical industry.
Founded in 1929, Reig Jofre was born with the firm belief that science that matters should be accessible to everyone — bringing essential and innovative solutions to people around the world. The company plays a crucial role between research and treatment, delivering pioneering, high-impact solutions thanks to state-of-the-art production technologies, ongoing collaboration with innovative companies, researchers, multinationals and startups, and sustained investment in R&D&I.
Business Areas
- Pharmaceutical Technologies, specializing in sterile injectable and lyophilized products, as well as penicillin-derived antibiotics.
- Specialty Pharmacare, focused primarily on dermatology and osteoarticular conditions.
- Consumer Healthcare, offering self-care products for end consumers under the Forté Pharma brand – a market leader in France, Belgium, Spain, and Portugal – as well as other OTC products in otorhinolaryngology.
Today, Reig Jofre ranks as the fifth-largest listed Spanish pharmaceutical company by revenue and stands as a benchmark in industrial capability and adaptability to global health needs.
Industrial and Commercial Footprint
The company operates four development and production centers across Europe (two in Toledo, one in Barcelona, and one in Malmö, Sweden), has its own commercial teams in Spain, France, Portugal, Belgium, Sweden, the United Kingdom, Poland and the Czech Republic, and a network of partners in more than 70 countries. Its workforce exceeds 1,400 professionals.
2024 Results
In 2024, Reig Jofre reported revenues of €339 million (+7% vs. 2023) and an EBITDA of €38 million (+8% vs. 2023).
Ignasi Biosca, CEO of Reig Jofre:
“A decade on the markets has given us discipline and vision. We continue investing in technology and talent to turn innovation into real health, with a purpose that remains unchanged: bringing the science that matters to more people — safely, with quality and trust.”
The Role of the Stock Market
Being listed on the Spanish stock exchanges has been a decisive factor in Reig Jofre’s journey, providing access to financing for growth, greater visibility, and enhanced credibility among investors and strategic partners.
Through this channel, the company has been able to drive innovation projects, strengthen its production capacity, and expand its international presence — consolidating its position as one of Spain’s leading listed pharmaceutical laboratories and gaining growing recognition across Europe.
“Opening up the company’s capital allowed us to welcome new travel companions while keeping the founding family as long-term supporters of the project.”